Cabozantinib (DB08875): A Comprehensive Monograph on its Pharmacology, Clinical Development, and Therapeutic Role

Section 1: Executive Summary and Drug Profile

1.1. Overview of Cabozantinib as a Multi-Targeted Tyrosine Kinase Inhibitor

Cabozantinib is an orally bioavailable small molecule that represents a significant therapeutic advance in the field of oncology. It functions as a potent, non-specific inhibitor of multiple receptor tyrosine kinases (RTKs), which are key mediators of cellular signaling pathways that drive cancer progression.[1] The fundamental mechanism of action of cabozantinib involves the simultaneous suppression of critical processes including tumor growth (oncogenesis), the formation of new tumor-supplying blood vessels (angiogenesis), and the spread of cancer to distant sites (metastasis).[1] This broad-spectrum activity against the core drivers of malignancy underpins its demonstrated efficacy across a diverse and expanding range of solid tumors, establishing it as a versatile and powerful agent in the modern anticancer armamentarium.

1.2. Key Identifiers, Formulations, and Brand Names (Cometriq® vs. Cabometyx®)

The drug is identified by its DrugBank ID DB08875 and Chemical Abstracts Service (CAS) Number 849217-68-1. During its development, it was also known by the codes XL184 and BMS-907351.[1] A crucial aspect of cabozantinib's clinical and commercial profile is the existence of two distinct brand names, which correspond to different formulations, approved dosages, and initial therapeutic indications.[8] Understanding this distinction is fundamental to appreciating its development history and appropriate clinical use.

• Cometriq®: This was the first formulation of cabozantinib to receive regulatory approval. It is supplied as capsules, available in 20 mg and 80 mg strengths.[11] Cometriq® was initially approved at a relatively high daily dose of 140 mg for the treatment of progressive, metastatic medullary thyroid cancer (MTC), a rare and aggressive malignancy.[1]
• Cabometyx®: This is a subsequent tablet formulation, available in 20 mg, 40 mg, and 60 mg strengths.[11] Cabometyx® is generally prescribed at a lower daily dose, typically 60 mg for monotherapy, and has been approved for a much wider range of indications. These include advanced renal cell carcinoma (RCC), hepatocellular carcinoma (HCC), differentiated thyroid cancer (DTC), and, most recently, pancreatic and extra-pancreatic neuroendocrine tumors (pNET/epNET).[2]

The development of these two distinct formulations was not merely a marketing choice but a deliberate and insightful clinical development strategy. The initial approval of the high-dose Cometriq® for MTC was accompanied by a significant toxicity profile, including a boxed warning for gastrointestinal perforations and hemorrhage.[14] To successfully expand into larger oncology indications like RCC, where patients might be on therapy for extended periods and the risk-benefit calculation is different, a more tolerable regimen was essential. The subsequent development of the lower-dose Cabometyx® tablet formulation allowed the manufacturer, Exelixis, Inc., to achieve a more manageable safety profile. This strategic decision to optimize the therapeutic index for each specific cancer was critical to the drug's widespread adoption, its expansion into broader patient populations, and its ultimate commercial success.

1.3. Synopsis of Therapeutic Landscape and Clinical Significance

Cabozantinib has firmly established itself as a cornerstone therapy in several difficult-to-treat cancers. Its development trajectory showcases a masterful strategy of market expansion, beginning with an orphan indication (MTC) and progressively moving into major oncology markets such as RCC and HCC, and more recently into other rare tumor types like NETs.[14] The clinical significance of cabozantinib is underscored by its success in pivotal, head-to-head trials where it demonstrated superiority over established standards of care, such as everolimus and sunitinib in RCC.[19] Furthermore, its synergistic efficacy when used in combination with immune checkpoint inhibitors, notably nivolumab, has redefined first-line treatment paradigms in advanced RCC and highlighted its role as a key combination partner in the era of immuno-oncology.[22]

Section 2: Chemistry, Manufacturing, and Properties

2.1. Chemical Identity and Molecular Structure

Cabozantinib is a precisely defined small molecule with a complex structure that enables its multi-targeted kinase inhibition.

• Systematic Name (IUPAC): The formal chemical name for cabozantinib is N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide.[1]
• Chemical Description: From a chemical classification standpoint, cabozantinib is a dicarboxylic acid diamide. Its structure incorporates several key functional groups, including a quinoline ring system, an organofluorine component, and an aromatic ether linkage.[1] The core of the molecule is a cyclopropane-1,1-dicarboxamide scaffold. This central ring links two distinct aryl moieties: a (6,7-dimethoxyquinolin-4-yl)oxy-phenyl group on one amide nitrogen and a 4-fluorophenyl group on the other.[1]
• Molecular Formula: C28​H24​FN3​O5​.[6]
• Molecular Weight: The average molecular weight of the free base is approximately 501.51 g/mol.[1]

For clarity and reference, the key chemical and drug identifiers are consolidated in Table 2.1. This table provides a centralized resource for researchers, chemists, and regulatory specialists needing to cross-reference the compound in various databases or perform chemical calculations.

Table 2.1: Drug Identification and Chemical Properties

Property	Value	Source(s)
Common Name	Cabozantinib	1
DrugBank ID	DB08875	4
CAS Number	849217-68-1 (free base)	6
Other Identifiers	XL184, BMS-907351	1
Molecular Formula	C28​H24​FN3​O5​	6
Molecular Weight	501.51 g/mol	6
IUPAC Name	N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide	1
SMILES Code	O=C(C1(C(NC2=CC=C(F)C=C2)=O)CC1)NC3=CC=C(OC4=CC=NC5=CC(OC)=C(OC)C=C45)C=C3	7
InChI Key	ONIQOQHATWINJY-UHFFFAOYSA-N	7

2.2. Physicochemical Properties

• Appearance: In its pure form, cabozantinib is a white to off-white solid powder.[7]
• Solubility: It is characterized as being practically insoluble in aqueous media. However, it demonstrates good solubility in organic solvents such as dimethyl sulfoxide (DMSO), with concentrations of 50 mg/mL being achievable. Its solubility in ethanol is poor.[1]
• Stability and Storage: As a solid powder, cabozantinib is stable for at least two to four years when stored under recommended conditions, which include a temperature of -20°C and protection from light and moisture to prevent degradation.[23]

2.3. Synthesis and Manufacturing Processes

The synthesis of cabozantinib has undergone significant evolution, reflecting a drive towards greater efficiency, safety, and scalability as the drug transitioned from a clinical candidate to a globally marketed therapeutic.

• Route 1 (Traditional/Patented Method): An early, patented synthetic route involves a five-step reaction sequence. This process utilizes readily available raw materials such as diethyl malonate, 4-fluoroaniline, 4-chloro-6,7-dimethoxyquinoline, and 4-aminophenol. A key advantage of this route is that it avoids the use of more expensive starting materials like 1,1-cyclopropyl dicarboxylic acids. However, it involves multiple discrete steps that can be complex to scale for industrial production.[25]
• Route 2 (Improved Amidation Approach): A significant process improvement involves the direct condensation of two key intermediates: 4-(6,7-dimethoxyquinolin-4-yloxy)aniline and methyl 1-(4-fluorophenylcarbamoyl)cyclopropanecarboxylate. This reaction is facilitated by sodium methoxide and is designed to avoid the use of toxic acid chlorides and costly coupling reagents. Furthermore, this method simplifies purification by aiming for a process that does not require chromatographic separation, a major advantage in large-scale manufacturing.[26]
• Route 3 (Two-Step Cascaded Flow Process): The most advanced and efficient manufacturing process developed for cabozantinib is a two-step cascaded flow synthesis conducted in microreactors. This state-of-the-art approach begins with 1,1-cyclopropanedicarboxylic acid and utilizes milder, safer coupling reagents such as N,N'-carbonyldiimidazole (CDI) and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDCI) with 1-hydroxybenzotriazole (HOBt). This continuous synthesis method dramatically reduces the total reaction time to just 35 minutes and achieves an exceptionally high overall yield of 96.1% with a final product purity of 99.8%.[27] This route is highly optimized for large-scale, cost-effective, and environmentally friendlier production, making it ideal for a blockbuster drug.

The evolution in synthetic chemistry from complex, multi-step batch processes to this highly efficient continuous-flow system is a critical component of the cabozantinib story. Initial synthesis methods detailed in patents are often sufficient for producing material for early clinical trials but can be commercially unviable due to high costs, safety concerns (e.g., use of toxic reagents like oxalyl chloride [28]), or scalability challenges. As cabozantinib demonstrated its profound clinical value and moved toward blockbuster status, a strong economic and operational incentive emerged to optimize its manufacturing. The development of the cascaded flow process represents a significant investment in process chemistry innovation. This innovation directly addresses the limitations of earlier methods by increasing yield, reducing waste, improving operator safety, and ultimately lowering the cost of goods. This demonstrates that the commercial success of cabozantinib is supported not only by its clinical efficacy but also by sophisticated chemical engineering that ensures a reliable and cost-effective global supply chain.

• Salification: The active pharmaceutical ingredient, cabozantinib free base, is frequently reacted with L-malic acid to produce cabozantinib s-malate. This salt form is used in the Cabometyx® tablets and is noted to have favorable physicochemical properties for formulation.[1]

Section 3: Comprehensive Pharmacological Profile

3.1. Mechanism of Action (MOA): A Multi-Kinase Inhibition Strategy

The therapeutic efficacy of cabozantinib is derived from its function as a potent inhibitor of a broad array of RTKs that are fundamentally involved in tumor cell survival, proliferation, angiogenesis, invasion, and metastasis.[1] Mechanistically, cabozantinib exerts its effect by competitively binding within the adenosine triphosphate (ATP)-binding pockets of these target kinases. This occupation of the ATP-binding site prevents the kinase from undergoing autophosphorylation, a critical step for its activation, thereby blocking the initiation of downstream intracellular signaling cascades that promote cancer growth.[30]

3.1.1. Primary Targets: MET, VEGFR, and RET Pathways

Cabozantinib demonstrates high-affinity binding and potent inhibition of several key RTKs that are often dysregulated in cancer.

• Vascular Endothelial Growth Factor Receptors (VEGFRs): Cabozantinib is an exceptionally potent inhibitor of VEGFR2, with a half-maximal inhibitory concentration (IC50​) of just 0.035 nM. It also strongly inhibits VEGFR1 and VEGFR3.[4] The VEGFR pathway is the principal driver of angiogenesis, the process by which tumors develop new blood vessels to secure a supply of oxygen and nutrients. By potently blocking this pathway, cabozantinib exerts a powerful anti-angiogenic effect, effectively disrupting the tumor's vascular supply and inhibiting its growth and ability to metastasize.[5]
• MET (Hepatocyte Growth Factor Receptor): Cabozantinib is also a strong inhibitor of the c-Met receptor, with an IC50​ of 1.3 nM.[4] The MET signaling pathway, when activated by its ligand HGF, is a key driver of tumor cell invasion, migration, and metastasis. Importantly, MET activation is also a known mechanism of resistance to therapies that target only the VEGFR pathway. By co-inhibiting both VEGFR and MET, cabozantinib can simultaneously block angiogenesis and a major pathway of evasive resistance.[32]
• RET (Rearranged during Transfection): Inhibition of the RET proto-oncogene (IC50​ = 5.2 nM) is a critical component of cabozantinib's activity, particularly in medullary thyroid cancer (MTC).[4] Activating mutations in the RET gene are the primary oncogenic driver in the vast majority of hereditary and sporadic MTC cases. Cabozantinib's ability to directly target this fundamental driver is central to its efficacy in this disease.

3.1.2. Secondary and Tertiary Targets

Beyond its primary targets, the therapeutic breadth of cabozantinib is enhanced by its ability to potently inhibit a range of other clinically relevant kinases. These include AXL (IC50​ = 7 nM), KIT (IC50​ = 4.6 nM), Fms-like tyrosine kinase 3 (FLT3) (IC50​ = 11.3 nM), and TIE-2 (IC50​ = 14.3 nM).[4] AXL, like MET, is another important mediator of invasion and a resistance pathway to anti-angiogenic therapy. KIT is a known oncogenic driver in certain tumors like gastrointestinal stromal tumors (GIST), while FLT3 is relevant in some hematologic malignancies. This broad activity contributes to its effects across different tumor histologies and may help to overcome or delay the development of treatment resistance.

Table 3.1: Summary of Key Kinase Targets and IC50 Values

Kinase Target	IC50​ (nM)	Primary Associated Pathway / Role	Source(s)
VEGFR2	0.035	Angiogenesis, Vascular Permeability	6
c-Met	1.3	Invasion, Metastasis, Resistance	6
KIT	4.6	Oncogenesis (e.g., GIST), Hematopoiesis	6
RET	5.2	Oncogenesis (MTC, NSCLC)	24
AXL	7	Invasion, Metastasis, Resistance, Immunity	6
FLT3	11.3	Hematopoiesis, Oncogenesis (AML)	6
TIE-2	14.3	Angiogenesis, Vascular Stability	24
VEGFR1	-	Angiogenesis	4
VEGFR3	-	Lymphangiogenesis	4
TRKB	-	Neuronal Survival, Oncogenesis	4
ROS1	-	Oncogenesis (NSCLC)	4
TYRO3	-	Immune Modulation (TAM Kinase)	30
MER	-	Immune Modulation (TAM Kinase)	33

3.1.3. Immunomodulatory Effects via TAM Kinase Inhibition

A particularly sophisticated aspect of cabozantinib's mechanism is its ability to modulate the tumor immune microenvironment. It achieves this, in part, by inhibiting the TAM family of kinases: TYRO3, AXL, and MER.[30] These kinases are expressed on various immune cells and are involved in suppressing the innate immune response, promoting an immunosuppressive environment that allows the tumor to evade immune surveillance. By inhibiting the TAM kinases, cabozantinib can help to reverse this immunosuppression, potentially reducing the population of suppressive immune cells (like M2-polarized macrophages and myeloid-derived suppressor cells) and enhancing the activity of cytotoxic T-cells.[30]

This immunomodulatory property provides a powerful biological rationale for the observed synergy between cabozantinib and immune checkpoint inhibitors (ICIs) like nivolumab. The combination is not merely additive; it is a complementary attack. Cabozantinib works to create a more "inflamed" or immune-permissive tumor microenvironment, making the cancer more "visible" to the immune system. The ICI then acts to "release the brakes" on the T-cells, allowing them to mount a more effective anti-tumor attack. This dual mechanism helps explain the profound success of the cabozantinib-nivolumab combination in clinical trials.

The overall mechanism of cabozantinib can be conceptualized as a multi-pronged assault on the cancer ecosystem. While early TKIs were often more specific, tumors frequently developed resistance by activating alternative signaling pathways. Cabozantinib's broad-spectrum inhibition preemptively targets several of these key pathways—VEGFR, MET, and AXL—simultaneously. Since MET and AXL are well-established escape pathways that drive resistance to pure VEGFR inhibitors [32], by hitting these targets concurrently, cabozantinib not only functions as a potent primary therapy but may also inherently delay or overcome mechanisms of acquired resistance. This explains its robust efficacy in patients who have already progressed on prior VEGFR-targeted therapies.[19]

3.2. Pharmacokinetics: Absorption, Distribution, Metabolism, and Excretion (ADME)

The pharmacokinetic profile of cabozantinib informs its dosing schedule, potential for interactions, and use in specific patient populations.

• Absorption: Following oral administration, cabozantinib is absorbed, with peak plasma concentrations (Tmax​) being achieved within 2 to 5 hours.[4] A significant food effect exists; administration with a high-fat meal can substantially increase exposure. Therefore, it is directed that the drug be taken on an empty stomach, with patients instructed not to eat for at least two hours before and one hour after taking their dose.[16]
• Distribution: Cabozantinib is widely distributed throughout the body, as indicated by its large apparent volume of distribution (Vd​) of approximately 349 L. It is also extensively bound to human plasma proteins, with a binding percentage of 99.7% or greater.[4] This high degree of protein binding means that only a small fraction of the drug is free and pharmacologically active at any given time.
• Metabolism: Cabozantinib undergoes extensive metabolism, primarily in the liver. The major enzyme responsible for its biotransformation is cytochrome P450 3A4 (CYP3A4). A minor metabolic pathway involves CYP2C9. The primary metabolic reaction is oxidation, leading to the formation of an N-oxide metabolite, which is one of several metabolites produced.[1] The heavy reliance on CYP3A4 for metabolism is the basis for its significant drug-drug interaction potential.
• Excretion: The elimination of cabozantinib and its metabolites occurs through two main routes. The majority is excreted in the feces (approximately 54% of the administered dose), with a smaller portion eliminated via the urine (approximately 27%).[4]
• Half-Life and Clearance: Cabozantinib is characterized by a long terminal half-life (t1/2​), which is approximately 55 hours. This long half-life supports a convenient once-daily dosing regimen. At steady-state, the apparent clearance (CL/F) is approximately 4.4 L/hr.[4]

Table 3.2: Summary of Pharmacokinetic Parameters of Cabozantinib

Parameter	Value	Clinical Implication	Source(s)
Time to Peak Concentration (Tmax​)	2–5 hours	Rapid absorption after oral dose	4
Volume of Distribution (Vd​)	~349 L	Wide distribution into tissues	4
Plasma Protein Binding	≥99.7%	Low fraction of free drug; potential for displacement interactions	4
Primary Metabolic Enzyme	CYP3A4	High potential for drug-drug interactions with CYP3A4 inhibitors/inducers	1
Major Metabolite	N-oxide product	Primary product of hepatic metabolism	1
Route of Elimination	~54% Feces, ~27% Urine	Primarily fecal elimination of drug and metabolites	4
Biological Half-life (t1/2​)	~55 hours	Supports once-daily dosing regimen	4
Clearance (CL/F)	~4.4 L/hr	Rate of drug removal from the body at steady state	4

Section 4: Clinical Efficacy Across Approved Indications

The clinical development of cabozantinib has been marked by a series of successful, well-designed pivotal trials that have systematically established its efficacy across a growing number of solid tumors. Its journey from an orphan drug to a broad-spectrum oncologic agent is a testament to its potent mechanism of action and a strategic clinical trial program.

4.1. Medullary Thyroid Cancer (MTC)

The first indication for cabozantinib was in MTC, a rare neuroendocrine tumor for which treatment options were limited.

• Pivotal Trial: EXAM (NCT00704730)
• Design: The EXAM trial was an international, multicenter, randomized, double-blind, placebo-controlled phase 3 study that enrolled 330 patients with documented progressive, metastatic MTC.[14]
• Treatment Arms: Patients were randomized in a 2:1 ratio to receive either cabozantinib (marketed as Cometriq®) at a dose of 140 mg orally once daily or a matching placebo.[14]
• Primary Endpoint: The primary measure of efficacy was progression-free survival (PFS), assessed by an independent radiology review committee.
• Key Results: The trial met its primary endpoint with high statistical significance. Patients treated with cabozantinib experienced a median PFS of 11.2 months, compared to just 4.0 months for patients in the placebo arm (Hazard Ratio not explicitly stated in snippets but p < 0.0001).[14] The objective response rate (ORR), a secondary endpoint, was 27% in the cabozantinib group versus 0% in the placebo group (p < 0.0001).[14] A significant benefit in overall survival (OS) was not demonstrated in the final analysis, a point that has been noted in subsequent health technology and economic assessments.[14]
• Significance: The robust PFS benefit observed in the EXAM trial led to the first regulatory approval for cabozantinib (as Cometriq®) by the U.S. Food and Drug Administration (FDA) in November 2012. This established cabozantinib as a new standard of care for patients with this rare and aggressive form of thyroid cancer.[13]

4.2. Renal Cell Carcinoma (RCC)

Cabozantinib's most significant impact has been in the treatment of advanced RCC, where it has redefined the therapeutic landscape in multiple settings. The clinical development strategy in RCC exemplifies an approach of systematically challenging and displacing existing standards of care.

4.2.1. Second-Line Monotherapy: The METEOR Trial (NCT01865747)

• Design: METEOR was a large, randomized, open-label, phase 3 trial that enrolled 658 patients with advanced RCC who had progressed after at least one prior VEGFR-targeted therapy.[19] This was an active-comparator trial, designed not just to show activity but to prove superiority over an existing standard.
• Treatment Arms: Patients were randomized 1:1 to receive either cabozantinib (as Cabometyx®) 60 mg daily or everolimus 10 mg daily, which was a standard second-line treatment at the time.[19]
• Endpoints: The primary endpoint was PFS. Key secondary endpoints included OS and ORR.
• Key Results: Cabozantinib demonstrated statistically significant and clinically meaningful superiority over everolimus across all three key efficacy parameters.
• PFS: Median PFS was 7.4 months for cabozantinib versus 3.8 months for everolimus (HR 0.58; 95% CI: 0.45, 0.74; p < 0.0001).[19]
• OS: Median OS was 21.4 months for cabozantinib versus 16.5 months for everolimus (HR 0.66; 95% CI: 0.53, 0.83; p = 0.0003).[19]
• ORR: The confirmed response rate was 17% for cabozantinib versus 3% for everolimus.[19]
• Significance: The compelling results of METEOR, particularly the significant OS benefit, were practice-changing. They led to the FDA approval of Cabometyx® in April 2016 for the treatment of advanced RCC in patients who have received prior anti-angiogenic therapy, establishing its superiority over everolimus and making it a new standard of care in the second-line setting.[19]

4.2.2. First-Line Monotherapy (Intermediate/Poor Risk): The CABOSUN Trial (NCT01835158)

• Design: Building on its second-line success, the CABOSUN trial was a randomized, open-label, phase 2 study designed to challenge the first-line standard of care. It enrolled 157 treatment-naïve patients with intermediate- or poor-risk advanced RCC.[21]
• Treatment Arms: Patients were randomized to receive either cabozantinib 60 mg daily or sunitinib 50 mg daily (on a 4-weeks-on, 2-weeks-off schedule), the long-standing first-line standard.[21]
• Primary Endpoint: The primary endpoint was PFS.
• Key Results: CABOSUN met its primary endpoint, demonstrating that cabozantinib led to a clinically meaningful and statistically significant 52% reduction in the rate of disease progression or death compared to sunitinib (HR 0.48; 95% CI 0.31-0.74, per independent review committee).[21] Median PFS was improved to 8.6 months with cabozantinib versus 5.3 months with sunitinib.[38]
• Significance: Despite being a phase 2 trial, the strength of the data was sufficient to support the expansion of Cabometyx®'s indication to the first-line treatment of advanced RCC. This FDA approval in December 2017 directly challenged sunitinib's decade-long incumbency and positioned cabozantinib as a key player in the front-line setting.[21]

4.2.3. First-Line Combination Therapy with Nivolumab: The CheckMate-9ER Trial (NCT03141177)

• Design: The CheckMate-9ER trial was a landmark, open-label, randomized, multi-national phase 3 study that enrolled 651 patients with previously untreated advanced RCC, regardless of risk status.[22] This trial tested the hypothesis that combining cabozantinib's multi-targeted TKI activity with the immune-boosting effects of a checkpoint inhibitor would be superior to TKI monotherapy.
• Treatment Arms: Patients were randomized to receive either the combination of cabozantinib (at a reduced dose of 40 mg daily) plus the PD-1 inhibitor nivolumab, or sunitinib monotherapy.[22]
• Endpoints: The primary endpoint was PFS. Key secondary endpoints included OS and ORR.
• Key Results: The combination regimen demonstrated profound superiority over sunitinib across all efficacy endpoints.
• PFS: The combination doubled the median PFS to 16.6 months versus 8.3 months for sunitinib (HR 0.51; 95% CI: 0.41, 0.64; p < 0.0001).[41]
• OS: The combination reduced the risk of death by 40% compared to sunitinib (HR 0.60; 98.89% CI: 0.40, 0.89; p = 0.0010).[41]
• ORR: The response rate was more than doubled, at 55.7% for the combination versus 27.1% for sunitinib.[41]
• Significance: The CheckMate-9ER trial was practice-defining. Its results established the cabozantinib-nivolumab combination as a new premier first-line standard of care for advanced RCC. This led to rapid regulatory approvals by the FDA in January 2021 and the European Medicines Agency (EMA) in March 2021, solidifying the central role of TKI + ICI combinations in this disease.[16]

4.3. Hepatocellular Carcinoma (HCC)

• Pivotal Trial: CELESTIAL (NCT01908426)
• Design: The CELESTIAL trial was a global, randomized, double-blind, placebo-controlled phase 3 study that enrolled 707 patients with advanced HCC who had progressed on or were intolerant to prior sorafenib, the only approved first-line therapy at the time.[4]
• Treatment Arms: Patients were randomized 2:1 to receive either cabozantinib 60 mg daily or placebo.[38]
• Primary Endpoint: The primary endpoint was Overall Survival (OS).
• Key Results: The trial met its primary endpoint, with cabozantinib demonstrating a statistically significant and clinically meaningful improvement in OS compared to placebo. The EMA summary noted that cabozantinib prolonged survival in this patient population.[38]
• Significance: These results led to the FDA approval of Cabometyx® in January 2019 for the treatment of patients with HCC previously treated with sorafenib. This provided an important new therapeutic option in the second-line setting for a cancer with a very poor prognosis and limited effective therapies.[4]

4.4. Differentiated Thyroid Cancer (DTC)

• Pivotal Trial: COSMIC-311 (NCT03690388)
• Design: This was an international, randomized, double-blind, placebo-controlled phase 3 trial for patients with radioactive iodine (RAI)-refractory DTC that had progressed during or following treatment with up to two prior VEGFR-targeting TKIs.[35] This trial addressed a population with a significant unmet need.
• Treatment Arms: Patients were randomized 2:1 to receive cabozantinib 60 mg daily or placebo.[35]
• Primary Endpoints: The co-primary endpoints were PFS and ORR.
• Key Results: The trial met its primary endpoint for PFS with impressive results. The median PFS was 11.0 months in the cabozantinib arm compared to a mere 1.9 months in the placebo arm, representing a 78% reduction in the risk of progression or death (HR 0.22; 95% CI: 0.15, 0.31).[35] The co-primary endpoint of ORR was not formally met at the time of analysis.[35]
• Significance: The dramatic PFS benefit led to an FDA approval in September 2021 for adult and pediatric patients (aged 12 years and older) with advanced, RAI-refractory DTC who have progressed on prior therapy. This was the first therapy approved for this specific patient population and the first pediatric approval for cabozantinib.[16]

4.5. Pancreatic and Extra-Pancreatic Neuroendocrine Tumors (pNET/epNET)

• Pivotal Trial: CABINET (NCT03375320)
• Design: The CABINET trial was a randomized, double-blind, placebo-controlled phase 3 study with two independent cohorts: one for patients with pancreatic NETs (pNET) and another for patients with extra-pancreatic NETs (epNET). It enrolled patients with progressive disease following prior standard therapies.[20]
• Treatment Arms: In both cohorts, patients were randomized 2:1 to receive cabozantinib 60 mg daily or placebo.[20]
• Primary Endpoint: The primary endpoint was PFS, assessed separately in each cohort.
• Key Results: The trial was stopped early by the independent data and safety monitoring board due to overwhelming efficacy observed at a planned interim analysis.[46]
• pNET cohort: Cabozantinib demonstrated a median PFS of 13.8 months versus 3.3 months for placebo (HR 0.22; 95% CI: 0.12, 0.41; p < 0.0001). The ORR was 18% with cabozantinib versus 0% with placebo.[20]
• epNET cohort: Cabozantinib showed a median PFS of 8.5 months versus 4.2 months for placebo (HR 0.40; 95% CI: 0.26, 0.61; p < 0.0001). The ORR was 5% with cabozantinib versus 0% with placebo.[20]
• Significance: The remarkable results from CABINET led to a major FDA approval in March 2025 for both pNET and epNET in adult and pediatric patients 12 years and older. This landmark approval established cabozantinib as the first and only systemic therapy approved for previously treated, well-differentiated NETs regardless of the primary tumor's site of origin, addressing a major unmet need for this diverse group of rare cancers.[20]

Table 4.1: Detailed Summary of Pivotal Clinical Trials by Indication

Indication	Trial Name (NCT ID)	Phase	# Pts	Treatment Arms	Primary Endpoint	Key Efficacy Results (Median PFS / OS; ORR; HR)
Medullary Thyroid Cancer (MTC)	EXAM (NCT00704730)	3	330	Cabozantinib 140 mg vs. Placebo	PFS	PFS: 11.2 vs. 4.0 mos; ORR: 27% vs. 0% 14
Renal Cell Carcinoma (RCC) - 2nd Line	METEOR (NCT01865747)	3	658	Cabozantinib 60 mg vs. Everolimus	PFS	PFS: 7.4 vs. 3.8 mos (HR 0.58); OS: 21.4 vs. 16.5 mos (HR 0.66); ORR: 17% vs. 3% 19
RCC - 1st Line (Int/Poor Risk)	CABOSUN (NCT01835158)	2	157	Cabozantinib 60 mg vs. Sunitinib	PFS	PFS: 8.6 vs. 5.3 mos (HR 0.48) 21
RCC - 1st Line Combination	CheckMate-9ER (NCT03141177)	3	651	Cabozantinib 40 mg + Nivolumab vs. Sunitinib	PFS	PFS: 16.6 vs. 8.3 mos (HR 0.51); OS: NE vs. NE (HR 0.60); ORR: 55.7% vs. 27.1% 22
Hepatocellular Carcinoma (HCC) - 2nd Line	CELESTIAL (NCT01908426)	3	707	Cabozantinib 60 mg vs. Placebo	OS	Statistically significant improvement in OS vs. placebo 38
Differentiated Thyroid Cancer (DTC)	COSMIC-311 (NCT03690388)	3	187	Cabozantinib 60 mg vs. Placebo	PFS, ORR	PFS: 11.0 vs. 1.9 mos (HR 0.22); ORR endpoint not met 35
Pancreatic NET (pNET)	CABINET (NCT03375320)	3	99	Cabozantinib 60 mg vs. Placebo	PFS	PFS: 13.8 vs. 3.3 mos (HR 0.22); ORR: 18% vs. 0% 20
Extra-pancreatic NET (epNET)	CABINET (NCT03375320)	3	199	Cabozantinib 60 mg vs. Placebo	PFS	PFS: 8.5 vs. 4.2 mos (HR 0.40); ORR: 5% vs. 0% 20

Section 5: Safety, Tolerability, and Risk Management

The potent, broad-spectrum mechanism of action that drives cabozantinib's efficacy is also directly responsible for its complex and challenging safety profile. Effective clinical use of cabozantinib is therefore contingent upon a deep understanding of its potential toxicities and a proactive approach to their management.

5.1. Comprehensive Adverse Event Profile

• Common Adverse Reactions (≥20%): In monotherapy settings, the most frequently reported adverse events (AEs) are gastrointestinal and constitutional. These include diarrhea, fatigue, palmar-plantar erythrodysesthesia (PPE, or hand-foot skin reaction), decreased appetite, hypertension, nausea, vomiting, weight loss, and constipation.[16]
• Combination Therapy Adverse Events (with nivolumab): When combined with the checkpoint inhibitor nivolumab, the AE profile overlaps significantly but also shows increased rates of certain toxicities. These include high rates of hepatotoxicity (manifesting as elevated alanine transaminase and aspartate transaminase), stomatitis (mouth sores), rash, hypothyroidism, and musculoskeletal pain, in addition to the common AEs seen with monotherapy.[16]
• Common Laboratory Abnormalities (≥25%): Regular laboratory monitoring is essential, as cabozantinib is associated with a high incidence of abnormalities. These commonly include increased liver enzymes (AST, ALT), lymphopenia, increased alkaline phosphatase, hypocalcemia, neutropenia, thrombocytopenia, and hypophosphatemia.[17]

5.2. Boxed Warnings, Contraindications, and Special Precautions

Regulatory agencies have highlighted several serious risks associated with cabozantinib therapy.

• Boxed Warning (Cometriq® formulation): The FDA prescribing information for the Cometriq® (capsule) formulation includes a prominent boxed warning. This warning highlights the risk of serious and sometimes fatal gastrointestinal (GI) perforations and fistulas, as well as the risk of severe and potentially fatal hemorrhage (bleeding).[8] While the Cabometyx® label does not carry a boxed warning, these risks are still listed as key warnings and precautions.
• Key Warnings and Precautions (All formulations): The labels for both Cometriq® and Cabometyx® list numerous serious potential risks that require careful monitoring and management:
• Hemorrhage: There is a significant risk of severe bleeding events, which can be fatal. The drug should not be administered to patients with a recent history of severe hemorrhage.[17]
• Perforations and Fistulas: Formation of holes in the GI tract (perforations) or abnormal connections between organs (fistulas) can occur and may be fatal. Patients should be monitored for symptoms like severe abdominal pain.[4]
• Thrombotic Events: Cabozantinib increases the risk of both arterial and venous blood clots (thromboembolism), which can lead to serious events such as myocardial infarction (heart attack) and cerebral infarction (stroke).[17]
• Hypertension and Hypertensive Crisis: High blood pressure is a very common and potentially severe side effect. Blood pressure must be well-controlled before starting therapy and monitored regularly throughout.[33]
• Diarrhea, PPE, and Hepatotoxicity: These are common, can be severe, and are frequent reasons for dose modifications.[33]
• Osteonecrosis of the Jaw (ONJ): This serious condition, involving death of jaw bone tissue, has been reported. Patients should be advised to maintain good oral hygiene, and invasive dental procedures should be avoided during treatment if possible.[15]
• Impaired Wound Healing: Cabozantinib can interfere with the healing process. Treatment should be stopped at least 3 weeks prior to elective surgery and not resumed until the wound is adequately healed.[17]
• Reversible Posterior Leukoencephalopathy Syndrome (RPLS): This is a rare but serious neurological disorder characterized by headache, seizures, and vision loss, which requires immediate discontinuation of the drug.[15]
• Thyroid Dysfunction and Hypocalcemia: Cabozantinib can cause hypothyroidism and low blood calcium levels, requiring regular monitoring and supplementation as needed.[33]
• Contraindications: Cabozantinib is contraindicated in pregnancy. It has not been tested in pregnant women but is known to cause fetal harm in animal studies. Women of reproductive potential must be advised of the risk and use effective contraception during treatment and for a period after the last dose.[8]

5.3. Management of Key Adverse Events

Proactive and aggressive management of side effects is critical to maintaining patients on therapy, which allows them to derive the maximum clinical benefit. This involves thorough patient education before starting treatment, regular monitoring, and prompt intervention.

• Hypertension: Blood pressure should be monitored at baseline and regularly throughout treatment. It should be managed with standard anti-hypertensive medications. For uncontrolled hypertension, the cabozantinib dose should be withheld and then resumed at a reduced level once controlled. For hypertensive crisis, the drug must be permanently discontinued.[51]
• Diarrhea: Patients should be educated on dietary modifications and the use of standard anti-diarrheal agents like loperamide. For Grade 3 diarrhea or intolerable Grade 2 diarrhea, treatment should be interrupted until resolution to Grade 1, at which point it can be resumed at a lower dose.[46]
• Palmar-Plantar Erythrodysesthesia (PPE): Management includes supportive care measures such as the use of moisturizing creams, wearing cushioned footwear, and avoiding pressure on the hands and feet. For Grade 3 PPE or intolerable Grade 2 PPE, treatment should be interrupted until resolution to Grade 1 and then resumed at a reduced dose.[46]

5.4. Drug-Drug and Drug-Food Interactions

Cabozantinib's metabolism via CYP3A4 makes it highly susceptible to interactions with other drugs that inhibit or induce this enzyme.

• Strong CYP3A4 Inhibitors: Co-administration with strong inhibitors of CYP3A4 (e.g., ketoconazole, clarithromycin, ritonavir) can significantly increase the plasma concentration and exposure of cabozantinib, thereby increasing the risk of toxicity. This combination should be avoided if possible. If it cannot be avoided, a dose reduction of cabozantinib is mandatory.[4]
• Strong CYP3A4 Inducers: Co-administration with strong inducers of CYP3A4 (e.g., rifampin, carbamazepine, phenytoin, St. John's Wort) can significantly decrease the plasma concentration of cabozantinib, which may lead to a loss of efficacy. This combination should also be avoided. If it is necessary, an increase in the cabozantinib dose is recommended.[33]
• Food and Grapefruit: Cabozantinib must be taken on an empty stomach to ensure consistent absorption. Patients must avoid eating grapefruit or drinking grapefruit juice, as grapefruit is a well-known strong inhibitor of CYP3A4 and can dangerously increase cabozantinib levels.[17]

5.5. Dosing, Administration, and Modifications for Special Populations

• Standard Dosing: The recommended dose varies by brand and indication. For Cabometyx® monotherapy in RCC, HCC, and DTC, the standard adult dose is 60 mg once daily. For the RCC combination with nivolumab, the Cabometyx® dose is 40 mg once daily. For MTC, the Cometriq® dose is 140 mg once daily.[15]
• Dose Reductions: A clear, structured dose reduction schedule is provided in the prescribing information to manage adverse reactions. For a starting dose of 60 mg, the typical reduction steps are to 40 mg, and then to 20 mg daily.[15]
• Hepatic Impairment: Since cabozantinib is metabolized by the liver, dose adjustments are necessary for patients with hepatic impairment. A reduced starting dose is required for patients with mild-to-moderate (Child-Pugh Class A or B) impairment. Use of cabozantinib should be avoided in patients with severe (Child-Pugh Class C) hepatic impairment.[15]
• Renal Impairment: No dose adjustment is required for patients with mild-to-moderate renal impairment. The drug has not been formally studied in patients with severe renal impairment or those on dialysis, so it should be used with caution in this population, though a dedicated trial is exploring its use in hemodialysis patients.[15]
• Pediatric Use: Cabozantinib is approved for use in pediatric patients aged 12 years and older for the treatment of DTC and NETs. The dosing is based on body weight, with patients weighing less than 40 kg receiving a lower starting dose (40 mg daily) than those weighing 40 kg or more (60 mg daily).[15]

The safety profile of cabozantinib can be described as a "double-edged sword." The on-target toxicities are a direct and predictable consequence of its powerful, broad-spectrum mechanism. For example, potent VEGFR inhibition, while critical for blocking tumor angiogenesis, logically leads to adverse events related to normal vascular function, such as hypertension, bleeding, and impaired wound healing.[30] Similarly, the high rates of diarrhea, fatigue, and PPE are known class effects for many TKIs, likely resulting from the inhibition of multiple kinases in healthy, rapidly dividing tissues throughout the body.[16] This creates a direct causal link: the very mechanism that makes the drug so effective also makes it inherently toxic. This reality necessitates the highly proactive and structured approach to toxicity management—involving dose holds, dose reductions, and aggressive supportive care—that is essential for keeping patients on this life-extending therapy. The evolution from the higher-dose, more toxic Cometriq® to the lower-dose Cabometyx® for broader indications is a clear case study in strategically optimizing this therapeutic index.

Section 6: Regulatory and Future Landscape

6.1. Global Regulatory History: A Chronological Analysis of FDA and EMA Approvals

The regulatory journey of cabozantinib is a story of strategic, evidence-based expansion. It began with a focused approval in a rare disease and systematically grew to encompass multiple major cancer types in both the United States and Europe, often achieving priority review status due to the strength of its clinical data. The chronological timeline in Table 6.1 illustrates this remarkable lifecycle management, showing how the drug climbed the treatment ladder from later lines to the front-line setting and established itself as a key combination agent.

Table 6.1: Chronological Regulatory Approval Timeline (FDA & EMA)

Date	Agency	Brand Name	Formulation	Indication	Key Trial	Source(s)
Nov 2012	FDA	Cometriq®	Capsule	Progressive, metastatic MTC	EXAM	13
Mar 2014	EMA	Cometriq®	Capsule	Progressive, unresectable, advanced/metastatic MTC	EXAM	36
Apr 2016	FDA	Cabometyx®	Tablet	Advanced RCC after prior anti-angiogenic therapy	METEOR	16
Sep 2016	EMA	Cabometyx®	Tablet	Advanced RCC after prior VEGF-targeted therapy	METEOR	34
Dec 2017	FDA	Cabometyx®	Tablet	First-line treatment of advanced RCC	CABOSUN	16
May 2018	EMA	Cabometyx®	Tablet	First-line treatment of int/poor-risk advanced RCC	CABOSUN	39
Jan 2019	FDA	Cabometyx®	Tablet	HCC previously treated with sorafenib	CELESTIAL	16
Jan 2021	FDA	Cabometyx®	Tablet	First-line advanced RCC (in combination with nivolumab)	CheckMate-9ER	16
Mar 2021	EMA	Cabometyx®	Tablet	First-line advanced RCC (in combination with nivolumab)	CheckMate-9ER	22
Sep 2021	FDA	Cabometyx®	Tablet	Advanced DTC after prior VEGFR therapy (adult & pediatric)	COSMIC-311	16
Apr 2022	EMA	Cabometyx®	Tablet	Advanced DTC after prior systemic therapy	COSMIC-311	57
Mar 2025	FDA	Cabometyx®	Tablet	Previously treated advanced pNET & epNET (adult & pediatric)	CABINET	20

6.2. Investigational Uses and Ongoing Clinical Research

The broad mechanism of action of cabozantinib has prompted its investigation in a vast number of other malignancies, positioning it as a drug with potential far beyond its current labels.

• Completed/Terminated Trials: Phase 2 trials have been completed, with varying degrees of success, in several other cancers, including hormone-receptor-positive and triple-negative breast cancer (NCT01441947, NCT01738438), castration-resistant prostate cancer (NCT01834651), and cholangiocarcinoma (NCT01954745).[58]
• Active and Recruiting Trials: An extensive portfolio of NCI-supported and industry-sponsored clinical trials continues to evaluate cabozantinib's potential. This research is exploring several key avenues:
• Novel Combination Therapies: Numerous trials are underway combining cabozantinib with other immunotherapies (e.g., atezolizumab, ipilimumab, pembrolizumab) and other classes of targeted agents (e.g., the radiopharmaceutical radium-223) across various tumor types.[40]
• New Cancer Indications: Active investigations are ongoing in non-small cell lung cancer (NSCLC) with RET rearrangements, melanoma, urothelial cancer, adrenal cortical cancer, gastroesophageal cancer, and various high-risk pediatric solid tumors.[44]
• New Therapeutic Settings: Research is also expanding into earlier stages of disease, such as the adjuvant setting (e.g., to prevent the return of mucosal melanoma after surgery), and in specific, hard-to-treat patient populations, such as RCC patients on hemodialysis.[56]

6.3. Future Perspectives and Potential in Combination Regimens

The future of cabozantinib appears to be heavily anchored in combination therapies. Its proven synergy with immune checkpoint inhibitors, driven by its immunomodulatory effects, makes it an attractive backbone for new combination regimens. The success of the CheckMate-9ER trial has provided a powerful proof-of-concept that is now being tested with other ICIs and in other tumor types. Expansion into earlier lines of therapy, such as the adjuvant and neoadjuvant settings, represents another major frontier for research. Furthermore, tumor types characterized by high expression of MET or AXL remain a key area of interest for future exploration. The development of next-generation multi-targeted TKIs, including Exelixis's own zanzalintinib, will inevitably be benchmarked against the high bar of efficacy and the known safety limitations set by cabozantinib, which will continue to influence the field for years to come.[50]

The sheer breadth of this ongoing research portfolio suggests that cabozantinib is viewed by the scientific community as a "pipeline in a pill." A typical drug is approved for one or two indications; cabozantinib has secured six major FDA-approved indications and is still being actively investigated across nearly every major solid tumor type.[16] This demonstrates a strong belief from both the manufacturer and the broader research community that its unique multi-targeted mechanism has applicability far beyond its current labels. Cabozantinib is not just a single drug but a therapeutic platform. Its success provides a powerful validation for the strategy of multi-targeted kinase inhibition, and the ongoing trials are systematically testing this platform across the full spectrum of oncology, with the potential to yield even more indication expansions in the future.

Section 7: Expert Synthesis and Strategic Analysis

7.1. Comparative Analysis: Cabozantinib vs. Other TKIs

A defining feature of cabozantinib's clinical profile is its demonstrated superiority in head-to-head trials against other established targeted therapies. In the METEOR trial, cabozantinib was superior to the mTOR inhibitor everolimus in second-line RCC, showing significant benefits in PFS, OS, and ORR.[19] More strikingly, in the CABOSUN trial, it outperformed sunitinib—a multi-targeted TKI and the long-time first-line standard—on the primary endpoint of PFS in treatment-naïve RCC patients.[21]

This competitive advantage may be attributable to cabozantinib's broader and more potent target inhibition profile. While sunitinib also targets VEGFR, its activity against other key pathways is less pronounced. Cabozantinib's potent co-inhibition of MET and AXL, in addition to VEGFR, likely confers a distinct advantage. As MET and AXL are known drivers of resistance to pure VEGFR inhibition, targeting them simultaneously may preemptively shut down these escape pathways, leading to more durable responses and improved survival outcomes. This broader activity, however, also contributes to a different and arguably more complex toxicity profile that requires diligent management.

7.2. The "Double-Edged Sword": Balancing Broad Efficacy with a Complex Safety Profile

The central theme that emerges from a comprehensive analysis of cabozantinib is the inextricable link between its powerful, broad-spectrum mechanism of action and its challenging, multi-system adverse event profile. It is a classic example of a therapeutic "double-edged sword." The very kinase inhibition that makes it a highly effective anticancer agent is also the source of its on-target toxicities. For instance, the potent blockade of VEGFR, essential for its anti-angiogenic effects, logically disrupts the function of normal blood vessels, leading to high rates of hypertension, bleeding risk, and impaired wound healing.

Therefore, clinical success with cabozantinib is not just about prescribing the drug; it is contingent upon expert, proactive management of its side effects to maintain dose intensity and keep patients on therapy long enough to benefit. The strategic evolution from the high-dose, highly toxic Cometriq® formulation for a rare cancer to the lower-dose, more manageable Cabometyx® formulation for broader indications stands as a prime case study in optimizing the therapeutic index. This move was essential for unlocking the drug's full potential across the wider landscape of oncology.

7.3. Strategic Implications for Clinical Practice and Future Drug Development

Cabozantinib has left an indelible mark on the field of oncology, with significant implications for both current clinical practice and future drug development.

• For Clinical Practice: Cabozantinib has fundamentally altered treatment algorithms in MTC, RCC, HCC, DTC, and NETs. In RCC, its use in combination with nivolumab has set a new benchmark for first-line therapy, requiring clinicians to become adept at managing the overlapping and distinct toxicities of both TKIs and immune checkpoint inhibitors. The availability of an effective agent in later-line settings for DTC and across the spectrum of NETs has filled major gaps in the therapeutic landscape.
• For Drug Development: The success of cabozantinib serves as a powerful validation for several key therapeutic strategies. First, it confirms the value of multi-targeted inhibition, particularly the approach of simultaneously targeting primary oncogenic drivers (like RET), the tumor microenvironment (via VEGFR), and key resistance pathways (like MET and AXL). Second, it provides one of the strongest proofs-of-concept for combining targeted therapies with immunotherapy, a paradigm that now dominates oncology research. The remarkable clinical and commercial success of cabozantinib has set an extremely high bar of efficacy that the next generation of TKIs and other targeted agents will be measured against. Its story will continue to inform and influence the design of cancer therapies for the foreseeable future.

Works cited

1. Cabozantinib | C28H24FN3O5 | CID 25102847 - PubChem, accessed July 15, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/25102847
2. Cabozantinib | C28H24FN3O5 | CID 25102847 - PubChem, accessed July 15, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Cabozantinib
3. Cabozantinib: MedlinePlus Drug Information, accessed July 15, 2025, https://medlineplus.gov/druginfo/meds/a616037.html
4. Cabozantinib: Uses, Interactions, Mechanism of Action | DrugBank ..., accessed July 15, 2025, https://go.drugbank.com/drugs/DB08875
5. pmc.ncbi.nlm.nih.gov, accessed July 15, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6166873/#:~:text=Cabozantinib%20exhibits%20anticancer%20activity%20through,pathways%20such%20as%20the%20VEGF.
6. Cabozantinib | XL184 | tyrosine kinase receptor inhibitor - TargetMol, accessed July 15, 2025, https://www.targetmol.com/compound/cabozantinib
7. Cabozantinib | BMS-907351 | XL-184 | CAS#849217-68-1 - MedKoo Biosciences, accessed July 15, 2025, https://www.medkoo.com/products/4613
8. Cabozantinib - Wikipedia, accessed July 15, 2025, https://en.wikipedia.org/wiki/Cabozantinib
9. en.wikipedia.org, accessed July 15, 2025, https://en.wikipedia.org/wiki/Cabozantinib#:~:text=Cabozantinib%2C%20sold%20under%20the%20brand,cell%20carcinoma%2C%20and%20hepatocellular%20carcinoma.
10. Definition of cabozantinib-s-malate - NCI Dictionary of Cancer Terms, accessed July 15, 2025, https://www.cancer.gov/publications/dictionaries/cancer-terms/def/cabozantinib-s-malate
11. Cabozantinib (oral route) - Mayo Clinic, accessed July 15, 2025, https://www.mayoclinic.org/drugs-supplements/cabozantinib-oral-route/description/drg-20060654
12. Cabozantinib - brand name list from Drugs.com, accessed July 15, 2025, https://www.drugs.com/ingredient/cabozantinib.html
13. Cometriq (cabozantinib) FDA Approval History - Drugs.com, accessed July 15, 2025, https://www.drugs.com/history/cometriq.html
14. FDA Approved Uses of Cabozantinib - CancerNetwork, accessed July 15, 2025, https://www.cancernetwork.com/view/fda-approved-uses-cabozantinib
15. Cometriq, Cabometyx (cabozantinib) dosing, indications, interactions, adverse effects, and more - Medscape Reference, accessed July 15, 2025, https://reference.medscape.com/drug/cometriq-cabometyx-cabozantinib-999791
16. Cabometyx (cabozantinib) FDA Approval History - Drugs.com, accessed July 15, 2025, https://www.drugs.com/history/cabometyx.html
17. COMETRIQ™ (cabozantinib) Label - accessdata.fda.gov, accessed July 15, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203756lbl.pdf
18. FDA Approves COMETRIQ™ (Cabozantinib) for Treatment of Progressive, Metastatic Medullary Thyroid Cancer - Exelixis, accessed July 15, 2025, https://ir.exelixis.com/news-releases/news-release-details/fda-approves-cometriqtm-cabozantinib-treatment-progressive
19. Cabozantinib (CABOMETYX) | FDA, accessed July 15, 2025, https://www.fda.gov/drugs/resources-information-approved-drugs/cabozantinib-cabometyx
20. FDA approves cabozantinib for adults and pediatric patients 12 years of age and older with pNET and epNET, accessed July 15, 2025, https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-cabozantinib-adults-and-pediatric-patients-12-years-age-and-older-pnet-and-epnet
21. Exelixis Announces U.S. FDA Approval of CABOMETYX® (cabozantinib) Tablets for Previously Untreated Advanced Renal Cell Carcinoma, accessed July 15, 2025, https://ir.exelixis.com/news-releases/news-release-details/exelixis-announces-us-fda-approval-cabometyxr-cabozantinib-0
22. Exelixis' Partner Ipsen Receives European Commission Approval for CABOMETYX® (cabozantinib) in Combination with OPDIVO® (nivolumab) as First-Line Treatment for Patients with Advanced Renal Cell Carcinoma, accessed July 15, 2025, https://ir.exelixis.com/news-releases/news-release-details/exelixis-partner-ipsen-receives-european-commission-approval-0
23. Cabozantinib - CAS-Number 849217-68-1 - Order from Chemodex, accessed July 15, 2025, https://www.chemodex.com/products/cabozantinib/
24. XL184 (BMS-907351, Cabozantinib, CAS Number: 849217-68-1) | Cayman Chemical, accessed July 15, 2025, https://www.caymanchem.com/product/18464/xl184
25. CN106632028A - Cabozantinib preparation method - Google Patents, accessed July 15, 2025, https://patents.google.com/patent/CN106632028A/en
26. (PDF) New Synthesis of Antitumor Drug Cabozantinib - ResearchGate, accessed July 15, 2025, https://www.researchgate.net/publication/313687545_New_Synthesis_of_Antitumor_Drug_Cabozantinib
27. Two-Step Continuous Synthesis of Cabozantinib in a Microreactor ..., accessed July 15, 2025, https://pubs.acs.org/doi/full/10.1021/acs.iecr.4c04100
28. CN112979544A - Preparation method of cabozantinib or salt thereof - Google Patents, accessed July 15, 2025, https://patents.google.com/patent/CN112979544A/en
29. Cabometyx, INN-Cabozantinib - EMA, accessed July 15, 2025, https://www.ema.europa.eu/en/documents/product-information/cabometyx-epar-product-information_en.pdf
30. What is the mechanism of action of Cabozantinib? - Patsnap Synapse, accessed July 15, 2025, https://synapse.patsnap.com/article/what-is-the-mechanism-of-action-of-cabozantinib
31. Cabozantinib (XL184) | VEGFR2/MET Inhibitor | MedChemExpress, accessed July 15, 2025, https://www.medchemexpress.com/Cabozantinib.html
32. [Cabozantinib: Mechanism of action, efficacy and indications] - PubMed, accessed July 15, 2025, https://pubmed.ncbi.nlm.nih.gov/28477875/
33. CABOMETYX® (cabozantinib) Mechanism of Action, accessed July 15, 2025, https://www.cabometyxhcp.com/mechanism-of-action
34. European Commission Approves CABOMETYX™ (cabozantinib) Tablets for the Treatment of Advanced Renal Cell Carcinoma Following VEGF-Targeted Therapy - Exelixis, accessed July 15, 2025, https://ir.exelixis.com/news-releases/news-release-details/european-commission-approves-cabometyxtm-cabozantinib-tablets
35. FDA Approval Summary: Cabozantinib for Differentiated Thyroid Cancer - PMC, accessed July 15, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9529996/
36. Cometriq | European Medicines Agency (EMA), accessed July 15, 2025, https://www.ema.europa.eu/en/medicines/human/EPAR/cometriq
37. Carcinoma Renal Cells Completed Phase 3 Trials for Cabozantinib (DB08875) - DrugBank, accessed July 15, 2025, https://go.drugbank.com/indications/DBCOND0041087/clinical_trials/DB08875?phase=3&status=completed
38. Cabometyx | European Medicines Agency (EMA), accessed July 15, 2025, https://www.ema.europa.eu/en/medicines/human/EPAR/cabometyx
39. European Commission approves Ipsen's Cabometyx® (cabozantinib) for the first-line treatment of adults with intermediate- or poor- risk advanced renal cell carcinoma, accessed July 15, 2025, https://www.ipsen.com/press-releases/european-commission-approves-ipsens-cabometyx-cabozantinib-for-the-first-line-treatment-of-adults-with-intermediate-or-poor-risk-advanced-renal-cell-carcinoma/
40. Cabozantinib Active Not Recruiting Phase 3 Trials for Renal Cell Carcinoma (RCC) Treatment - DrugBank, accessed July 15, 2025, https://go.drugbank.com/drugs/DB08875/clinical_trials?conditions=DBCOND0038284&phase=3&purpose=treatment&status=active_not_recruiting
41. Bristol Myers Squibb Receives European Commission Approval for Opdivo® (nivolumab) in Combination with Cabometyx® (cabozantinib) as First-Line Treatment for Patients with Advanced Renal Cell Carcinoma, accessed July 15, 2025, https://news.bms.com/news/details/2021/Bristol-Myers-Squibb-Receives-European-Commission-Approval-for-Opdivo-nivolumab-in-Combination-with-Cabometyx-cabozantinib-as-First-Line-Treatment-for-Patients-with-Advanced-Renal-Cell-Carcinoma/default.aspx
42. Cabozantinib plus Nivolumab Offers New First-Line Treatment Option for Patients with Advanced Renal-Cell Carcinoma - Oncology Practice Management, accessed July 15, 2025, https://oncpracticemanagement.com/issues/2020/november-2020-vol-10-no-11/cabozantinib-plus-nivolumab-offers-new-first-line-treatment-option-for-patients-with-advanced-renal-cell-carcinoma
43. Exelixis' Partner Ipsen Announces EMA Validation of the Application for a New Indication for CABOMETYX® (cabozantinib) for Previously Treated Advanced Hepatocellular Carcinoma, accessed July 15, 2025, https://ir.exelixis.com/news-releases/news-release-details/exelixis-partner-ipsen-announces-ema-validation-application-0
44. Clinical Policy: Cabozantinib (Cabometyx, Cometriq) - Superior Health Plan, accessed July 15, 2025, https://www.superiorhealthplan.com/content/dam/centene/Superior/policies/pharmacy-policies/Cabozantinib%20(Cabometyx,%20Cometriq)%20(CP.PHAR.111)%20(PDF).pdf
45. Exelixis Announces U.S. FDA Approval of CABOMETYX® (cabozantinib) for Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer, accessed July 15, 2025, https://ir.exelixis.com/news-releases/news-release-details/exelixis-announces-us-fda-approval-cabometyxr-cabozantinib-3
46. Detailed Results from Phase 3 CABINET Pivotal Trial Evaluating Cabozantinib in Advanced Neuroendocrine Tumors Presented at ESMO 2023 - Exelixis, accessed July 15, 2025, https://ir.exelixis.com/news-releases/news-release-details/detailed-results-phase-3-cabinet-pivotal-trial-evaluating
47. FDA Approves Cabozantinib for Advanced Neuroendocrine Tumors - Targeted Oncology, accessed July 15, 2025, https://www.targetedonc.com/view/fda-approves-cabozantinib-for-advanced-neuroendocrine-tumors
48. Study Details | Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors | ClinicalTrials.gov, accessed July 15, 2025, https://www.clinicaltrials.gov/study/NCT03375320
49. Cabozantinib Offers New Option for Rare Neuroendocrine Tumors | Research | AACR, accessed July 15, 2025, https://www.aacr.org/patients-caregivers/progress-against-cancer/cabozantinib-offers-new-option-for-rare-neuroendocrine-tumors/
50. Exelixis Announces U.S. FDA Approval of CABOMETYX® (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors, accessed July 15, 2025, https://ir.exelixis.com/news-releases/news-release-details/exelixis-announces-us-fda-approval-cabometyxr-cabozantinib-4
51. This label may not be the latest approved by FDA. For current ..., accessed July 15, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208692s012lbl.pdf
52. Cabometyx - This label may not be the latest approved by FDA. For current labeling information, please visit https://www.fda.gov/drugsatfda, accessed July 15, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208692s010lbl.pdf
53. CABOMETYX® (cabozantinib) Patient Website, accessed July 15, 2025, https://www.cabometyx.com/
54. This label may not be the latest approved by FDA. For current labeling information, please visit https://www.fda.gov/drugsatfda, accessed July 15, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208692s016lbl.pdf
55. Management of Adverse Events Associated with Cabozantinib Plus Nivolumab in Renal Cell Carcinoma: A Review - PubMed Central, accessed July 15, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9590624/
56. Study Details | Cabo-POLARIS : A Trial to Evaluate Cabozantinib Among Haemodialysied Patients | ClinicalTrials.gov, accessed July 15, 2025, https://clinicaltrials.gov/study/NCT05241561
57. EMA Recommends Extension of Therapeutic Indications for Cabozantinib - ESMO, accessed July 15, 2025, https://www.esmo.org/oncology-news/ema-recommends-extension-of-therapeutic-indications-for-cabozantinib
58. Cabozantinib Completed Phase 2 Trials for Breast Cancer Treatment | DrugBank Online, accessed July 15, 2025, https://go.drugbank.com/drugs/DB08875/clinical_trials?conditions=DBCOND0028036&phase=2&purpose=treatment&status=completed
59. Search for: Other terms: cabozantinib | Card Results - ClinicalTrials.gov, accessed July 15, 2025, https://www.clinicaltrials.gov/ct2/results?submit=Search&term=cabozantinib
60. Renal-cell Cancer Recruiting Phase 2 Trials for Cabozantinib (DB08875) | DrugBank Online, accessed July 15, 2025, https://go.drugbank.com/indications/DBCOND0053317/clinical_trials/DB08875?phase=2&status=recruiting
61. Clinical Trials Using Cabozantinib S-malate - NCI, accessed July 15, 2025, https://www.cancer.gov/research/participate/clinical-trials/intervention/cabozantinib-s-malate?pn=1
62. CABOMETYX (cabozantinib) - SPECIALTY GUIDELINE MANAGEMENT - CareFirst Provider Portal, accessed July 15, 2025, https://provider.carefirst.com/carefirst-resources/provider/pdf/drug/Cabometyx-Criteria.pdf
63. Study Details | Cabozantinib and Pembrolizumab for Advanced Metastatic Melanoma, accessed July 15, 2025, https://clinicaltrials.gov/study/NCT03957551